XLO · Xilio Therapeutics, Inc.

Summary

Xilio Therapeutics, Inc. furnished its corporate investor presentation dated March 9, 2026, under Item 7.01, detailing its pipeline of masked immuno-oncology therapies, clinical milestones, and preliminary estimated cash balance of $137.5 million as of December 31, 2025, providing investors with updates on development timelines and financial position.

Key takeaways

• Estimated cash and cash equivalents of $137.5M as of December 31, 2025
• Received $40M gross proceeds from follow-on offering in February 2026
• Potential up to $36.2M additional proceeds if Series C warrants exercised by end of 2026
• XTX501 IND submission mid 2026, initial Phase 1 data 2H 2027 in NSCLC
• PSMA+STEAP1 SEECR development candidate nomination Q2 2026, IND 2027
• Efarindodekin alfa option data package to Gilead 1H 2027
• Cash runway through end of 2027